Claims
- 1. An immunity adjuvant for vaccines comprising purified water-soluble proteoglycans obtained by a process which comprises at least one step in which crude membranal proteoglycans of Klebsiella, Serratia or Escherichia are treated in an aqueous medium with a reactant selected from the group consisting of bases and hypobromites followed by removal of the excess reactant and the insoluble residue, said purified water-soluble proteoglycans having the following composition by weight:
- ______________________________________hexoses 24-42%proteins 31-53%lipids 12-18%hexosamines 2-6%RNA <0.5%DNA <0.2%LPS <0.001%______________________________________
- 2. An adjuvant as set forth in claim 1 wherein the purified water-soluble proteoglycans have the following composition by weight:
- ______________________________________hexoses 37 .+-. 5%proteins 36.5 .+-. 5%lipids 15 .+-. 3%hexosamines 5 .+-. 2%RNA <0.5%DNA <<0.2%LPS <0.001%______________________________________
- 3. An adjuvant as set forth in claim 1 wherein the purified water-soluble proteoglycans have the following composition by weight:
- ______________________________________hexoses 29 .+-. 5%proteins 48 .+-. 5%lipids 15 .+-. 3%hexosamines 4 .+-. 2%RNA <0.5%DNA <<0.2%LPS <0.001%______________________________________
- 4. A vaccine based on bacterial ribosome and/or RNA as immunogenic agent containing as immunity adjuvant an effective amount of an adjuvant of the type set forth in claim 1.
- 5. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomes of Klebsiella pneumoniae 3.5 .mu.gribosomes of Streptococcus pneumoniae 3.0 .mu.gribosomes of Streptococcus pyogenes A.sub.12 3.0 .mu.gribosomes of Hemophilus influenzae 0.5 .mu.gproteoglycans of Klebsiella pneumoniae 15.0 .mu.g______________________________________
- 6. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomal RNA of Klebsiella pneumoniae 2.45 .mu.gribosomal RNA of Streptococcus pneumoniae 2.10 .mu.gribosomal RNA of Streptococcus pyogenes A.sub.12 2.10 .mu.gribosomal RNA of Hemophilus influenzae 0.35 .mu.gproteoglycans of Klebsiella pneumoniae 10.50 .mu.g______________________________________
- 7. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomes of Rothia dentocariosus 1.2 .mu.gribosomes of Actinomyces viscosus 1.2 .mu.gribosomes of Streptococcus mutans 0.8 .mu.gribosomes of Streptococcus salivarius 2.0 .mu.gribosomes of Lactobacillus casei 1.2 .mu.gproteoglycans of Klebsiella pneumoniae 9.6 .mu.g______________________________________
- 8. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomal RNA of Rothia dentocariosus 0.84 .mu.gribosomal RNA of Actinomyces viscosus 0.84 .mu.gribosomal RNA of Streptococcus mutans 0.56 .mu.gribosomal RNA of Streptococcus salivarius 1.40 .mu.gribosomal RNA of Lactobacillus casei 0.84 .mu.gproteoglycans of Klebsiella pneumoniae 6.72 .mu.g______________________________________
- 9. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomes of Corynebacterium acnes 2 .mu.gribosomes of Corynebacterium parvum 2 .mu.gribosomes of Streptococcus pyogenes 2 .mu.gribosomes of Staphylococcus epidermidis 2 .mu.gproteoglycans of Serratia marcescens 12 .mu.g______________________________________
- 10. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomal RNA of Corynebacterium acnes 1.4 .mu.gribosomal RNA of Corynebacterium parvum 1.4 .mu.gribosomal RNA of Streptococcus pyogenes 1.4 .mu.gribosomal RNA of Staphylococcus epidermidis 1.4 .mu.gproteoglycans of Serratia marcescems 8.4 .mu.g______________________________________
- 11. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomes of Escherichia coli 2 .mu.gribosomes of Streptococcus faecalis 2 .mu.gribosomes of Streptococcus H 2 .mu.gribosomes of Staphylococcus epidermidis 2 .mu.gribosomes of Candida albicans 2 .mu.gproteoglycans of Escherichia coli 15 .mu.g______________________________________
- 12. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomal RNA of Escherichia coli 1.4 .mu.gribosomal RNA of Streptococcus faecalis D 1.4 .mu.gribosomal RNA of Streptococcus H 1.4 .mu.gribosomal RNA of Staphylococcus epidermidis 1.4 .mu.gribosomal RNA of Candida albicans 1.4 .mu.gproteoglycans of Escherichia coli 10.5 .mu.g______________________________________
- 13. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomes of Bacterium coli 2 .mu.gribosomes of Salmonella paratyphi A 2 .mu.gribosomes of Salmonella paratyphi B 2 .mu.gribosomes of Shigella dysenteria 2 .mu.gribosomes of Enterococcus 2 .mu.gproteoglycans of Serratia marcescens 15 .mu.g______________________________________
- 14. A vaccine as set forth in claim 4 having the following composition:
- ______________________________________ribosomal RNA of Bacterium coli 1.4 .mu.gribosomal RNA of Salmonella paratyphi A 1.4 .mu.gribosomal RNA of Salmonella paratyphi B 1.4 .mu.gribosomal RNA of Shigella dysenteriae 1.4 .mu.gribosomal RNA of Enterococcus 1.4 .mu.gproteoglycans of Serratia marcescens 10.5 .mu.g______________________________________
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| 78 35649 |
Dec 1978 |
FRX |
|
Parent Case Info
This is a division of application Ser. No. 103,202, filed Dec. 13, 1979 now U.S. Pat. No. 4,297,272.
US Referenced Citations (5)
Foreign Referenced Citations (3)
| Number |
Date |
Country |
| 822817 |
May 1975 |
BEX |
| 839893 |
Sep 1976 |
BEX |
| 2253499 |
Jul 1975 |
FRX |
Divisions (1)
|
Number |
Date |
Country |
| Parent |
103202 |
Dec 1979 |
|
Patent Grant
4397838
